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1. Introduction  
The information that stems from the primary structure of DNA lies within the basis of every 
sign formation, although the regulation of any process occurs in different levels of cellular 
processes including transcription. In this context analysis of gene transcription is of great 
importance to improve our understanding of the pathogenesis of diverse disorders, and 
Parkinson’s disease (PD) is not an exception. However, each disease has its own unique 
etiopathogenesis within organs and tissues, which is caused by disease-specific processes in 
cells, as well as at the genetic level. Knowledge of the etiology and pathogenesis of diseases 
at a cellular level opens wide prospects for diagnosis and treatment, even for complex and 
incurable disorders such as PD. Therefore, it is necessary to study the pathogenesis of 
specific disease at the cellular and genetic levels. Accordingly, the expression profiles of 
large numbers of genes are being studied in different neurodegenerative disorders, 
including PD. Although the mechanisms that initiate neuronal pathology in sporadic PD 
remain largely obscure, in this chapter we have tried to summarize all current knowledge in 
the field of the PD transcriptomics. 
2. Analysis of gene expression in PD 
2.1 Analysis of gene expression in brain tissues 
The general approach in studying gene expression in PD is the analysis of transcript levels 
in tissues of the brain (the main organ that is affected in PD), which exhibit lesions that 
result in symptoms of PD. Unfortunately, only post-mortem tissues can be used in such 
studies. In addition, DNA microarrays are actively used in this type of study and there is a 
tendency to combine these data with the results of genome-wide association studies 
(GWAS) of single nucleotide polymorphisms (SNPs) and point mutations in PD (Elstner, 
2009). Combined analysis allows the identification of a number of candidate genes for 
further study; therefore, residual genes are more likely involved in the pathogenesis of PD 
(Horan, 2009, Noureddine, 2005).  
Thus, several tens of genes implicated in different metabolic pathways that are disturbed in 
PD have been identified during the analysis of transcription profiles in the substantia nigra 
of patients with PD. Mitochondrial dysfunction, oxidative stress, ubiquitin-proteasomal 
degradation of proteins, differentiation and functioning of dopaminergic (DA) neurons, DA 
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metabolism, inflammation, apoptosis, and several other processes are among such metabolic 
pathways.  
During the development of PD, there is a common tendency toward a decrease in the 
expression of genes that are involved in the pathogenesis of this disease (Table 1). According 
to some studies, the data expression of genes associated with mitochondrial functioning and 
oxidative stress (PARK7 and PINK) is downregulated. Although the levels of expression of 
genes involved in the ubiquitin-proteasomal system (UPS) were both increased and 
decreased in neurons of patients with PD, the downregulation of these genes is 
predominant especially regarding the expression of genes associated with monogenic forms 
of PD: SNCA, UCHL1, and ATP13A2. In addition, a lower number of transcripts were 
observed for lysosomal genes (mainly genes encoding proton-transporting ATP synthases) 
(Bossers, 2009, Duke, 2006, Elstner, 2009, Hauser, 2005, Simunovic, 2010, Simunovic, 2009).  
The very interesting work of Grünblatt and co-workers (Grünblatt, 2004) showed, for the 
first time, the global changes in gene expression in the substantia nigra pars compacta 
(SNpc) of postmortem parkinsonian brains compared with aged-matched controls. It was 
shown that major gene downregulation was observed in the signal transduction, protein 
degradation, dopaminergic transmission and metabolism, ion transport, and protein 
modification/phosphorylation, as well as in the energy pathways/glycolysis functional 
classes, in PD. Regarding genes that are upregulated differentially in PD, these cluster 
mainly in biological processes involving cell adhesion/cytoskeleton, extracellular-matrix 
components, cell cycle, protein modification/phosphorylation, protein metabolism, 
transcription, and inflammation/stress.  
Similar results were obtained later by Simunovic et al. (Simunovic, 2009), as one can see in 
the Table 1. Their data show a set of deregulated genes that are directly or indirectly 
involved in programmed cell death (PCD) confirming the current concept of the apoptotic 
death of the DA neuron. In addition, data show a dysfunction of both mitochondria and the 
UPS, which are major contributors to PCD and the pathogenesis of Parkinson’s disease 
(Duke, 2006). It should be noted that the expression of SNCA, a component of Lewy bodies 
and the pathologic accumulation of which is caused by oxidative stress, mitochondrial 
dysfunction, and impairment of cellular proteolytic mechanisms (Lundvig, 2005, as cited in 
Simunovic, 2009), was also deregulated. 
The expression of genes involved in the differentiation, survival, and functioning of DA 
neurons also changes. There is evidence of decreased expression of the NR4A2 transcription 
factor gene and of the ST13 chaperone gene. NR4A2 encodes a transcriptional factor that is 
required for the differentiation of postmitotic DA neurons and for the control of the expression 
of genes with protein products that are associated with DA synthesis and storage, notably, the 
tyrosine hydroxilase gene TH, the dopamine-transporter gene SLC6A3, the vesicular 
monoamine transporter gene VMAT2, and the amino acid decarboxylase gene AADC (Chinta 
& Andersen, 2005). In turn, decreased levels of expression of the ALDH, ARPP-21 and VMAT2 
genes are also possible markers of PD. The latter six genes are directly involved in the 
synthesis, metabolism and functioning of DA. A decrease in their expression may seriously 
disturb neurotransmitter storage and correlate with DA neurons dysfunction. The PDXK gene 
is also directly involved in the synthesis of DA. The increase of the expression of this gene in 
DA neurons can be explained by an adaptive mechanism of enhancement of DA metabolism 
in the residually functioning DA neurons of the substantia nigra, or by L-DOPA treatment 
(Tan, 2005). In PD, the expression of DA receptors also changes: the level of expression of D3 is 
reduced by 40-45% in the nucleus accumbens and in the tegmentum, and the level of D2 is 
increased by 15% in the tegmentum (Ryoo, 1998, Simunovic, 2010). 
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Decrease of expression Increase of expression Reference 
Mitochondrial functioning, oxidative phosphorylation 
Cytochrome c subunits 
genes 
 (Grünblatt, 2004, Simunovic, 
2010, Simunovic, 2009) 
NADH dehydrogenase 
subunits genes and 
NADH dehydrogenase-
affecting proteins genes 
 (Bossers, 2009, Hauser, 2005, 
Simunovic, 2010, Simunovic, 
2009) 
 MTND2 (subunit of 
NADH dehydrogenase) 
(Elstner, 2009) 
proton-transporting 
ATP-synthase complex 
genes, 
 (Simunovic, 2010, Simunovic, 
2009) 
other genes related with 
mitochondrial 
dysfunction 
 (Bossers, 2009, Elstner, 2009, 
Hauser, 2005, Simunovic, 2010, 
Simunovic, 2009) 
Oxidative stress 
Genes of different 
subunits of PIK3 
Genes of different 
subunits of PIK3 
(Grünblatt, 2004, Simunovic, 
2009) 
 
PINK1 и PARK7  (Simunovic, 2010, Simunovic, 
2009) 
Ubiquitin-proteasomal system of protein degradation, proteolysis/peptidolysis, 
lysosomes 
HIP2  
 
(Grünblatt, 2004, Moran, 2006, 
Simunovic, 2010, Simunovic, 
2009) 
ATP6V1E1  (Grünblatt, 2004, Simunovic, 
2009) 
ATP13A2, RIMS3 RIMS1 (Simunovic, 2010, Simunovic, 
2009) 
SNCA  (Dachsel, 2007, Simunovic, 2010, 
Simunovic, 2009) 
UCHL1  (Hauser, 2005, Simunovic, 2010, 
Simunovic, 2009) 
SKP1A  (Grünblatt, 2004) 
proton-transporting 
ATP-synthase complex 
genes 
 (Grünblatt, 2004, Simunovic, 
2010, Simunovic, 2009) 
Other genes involved in 
protein degradation, 
proteasome subunits 
genes 
 (Bossers, 2009, Grünblatt, 2004, 
Hauser, 2005, Simunovic, 2010, 
Simunovic, 2009) 
Table 1. Alterations in the transcription of genes involved in different pathways in brain 
tissues (substantia nigra) of patients with Parkinson’s disease. 
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Decrease of expression Increase of expression Reference 
Cytoskeleton, adhesion 
TUBB2 (tubulins), genes 
coding different 
proteins from kinesin 
family 
 (Grünblatt, 2004, Simunovic, 
2009) 
Cytoskeleton, cell 
adhesion proteins genes 
Cytoskeleton, cell 
adhesion proteins genes 
(Grünblatt, 2004, Simunovic, 
2009) 
MAPT  (Simunovic, 2010) 
Transcription, translation, chaperones, protein modification 
ST13  (Simunovic, 2010) 
NR4A2  (Bossers, 2009, Simunovic, 2009) 
Other genes involved in 
these pathways 
Other genes involved in 
these pathways 
(Grünblatt, 2004, Noureddine, 
2005, Simunovic, 2009) 
Signal transduction, synaptic transmission, neurotransmitters and neurotransmitter 
metabolism 
GABARAPL2 
 
Neurotrasmitters 
receptors genes 
(Grünblatt, 2004, Noureddine, 
2005, Simunovic, 2009) 
RIMS3  (Moran, 2006, Simunovic, 2010, 
Simunovic, 2009) 
ALDH1A1 PENK (Grünblatt, 2004) 
SEC22L1, ARPP-21  (Grünblatt, 2004, Zhang, 2005) 
 PDXK (DA synthesis) (Duke, 2007, Elstner, 2009) 
 SRGPA3 (Signal 
transduction) 
(Elstner, 2009) 
Genes involved in 
synaptic transmission 
 (Bossers, 2009, Noureddine, 
2005, Simunovic, 2009) 
Ion-channels genes Ion-channels genes (Simunovic, 2010, Simunovic, 
2009) 
Transport 
solute carrier family 
genes 
solute carrier family genes (Grünblatt, 2004, Simunovic, 
2009) 
Other transport protein 
genes VMAT 
Other transport protein 
genes 
 
(Grünblatt, 2004) 
 
TRAPPC4  (Elstner, 2009) 
Table 1. Alterations in the transcription of genes involved in different pathways in brain 
tissues (substantia nigra) of patients with Parkinson’s disease (continuation). 
The expression of genes involved in synaptic transmission and signal transduction is also 
altered in PD. Over the past years, there has been emerging evidence that the survival of DA 
neurons depends on their unique properties of electrical activity involving Na+, K+, and Ca2+ 
channels; moreover, the association between mitochondrial dysfunction and reactive oxygen 
species (ROS) production and K+ and Ca2+ channel activation has been suspected as a major 
contributor to the pathogenesis Parkinson’s disease (Michel, 2007 and Surmeier, 2007, as 
cited in Simunovic, 2009). Many molecules related to these mechanisms were shown as 
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being deregulated in the data set (Simunovic, 2009). In addition, the calcium channel 
subunit b3 (CACNB3), the ATPase type 13A2 (PARK9), and several subunits of Ca2+ 
transporting ATPases (ATP2A3, ATP2B2, and ATP2C1) were downregulated in PD further 
substantiating the involvement of a deficit in organelle function and of Ca2+ sequestering. A 
decrease in the level of the transcripts of the GABA receptor genes (GABRB1, 
GABARAPL1/3, and GABARAPL2) has also been discovered in PD, supporting the previous 
suggestion that GABAergic synapses are reduced in the substantia nigra of Parkinson’s 
disease brains, resulting in a reduction of DA neuron inhibition and an increase in 
neurotransmission and function of the remaining functional DA neurons (Miller & Federoff, 
2005, as cited in Simunovic, 2009). In contrast, the expression of genes encoding 
glutamatergic, cholinergic, somatostatinergic, and dopaminergic receptors was increased 
(Simunovic, 2009). The deregulation of several genes pointed to impairment of synaptic 
function and plasticity; some of these genes were also identified in other studies, such as 
SYNGR3, NSF, SV2B, SYN1, SYT1, and dynamin (Miller, 2006). The genes that were 
deregulated in the study of Simunovic mediate important mechanisms involved in the 
maintenance of synaptic function and integrity, such as those encoding a number of proteins 
from the SNARE complex (priming of the synaptic vesicle and synaptic vesicle surface 
proteins), which play a role in vesicle binding and fusion to the plasma membrane (Brunger, 
2005).  
However, the genes and mechanisms described above do not cover the whole spectrum of 
possible pathogenetic pathways underlying the sporadic form of PD. Several authors 
observed the upregulation of genes involved in cell adhesion and cytoskeleton (MAPT, 
PARVA (parvin, alpha), LGALS9, and selectin ligand P (SELPLG)), components of 
extracellular matrix (genes encoding structural proteins and phosphorylating proteins), cell 
cycle, inflammatory stress, and induced apoptosis (TRAF3, TNF receptor-associated factor 3) 
(Table 1). Simunovic et al. (Simunovic, 2009) detected deregulation of microtubulin-
associated genes, such as MAPT, MAPRE1, TCP1 (which participate in the unfolding of 
translated proteins in the cytosol, such as actin and tubulin (Stirling, 2007, as cited in 
Simunovic, 2009)) and of multiple subunits of tubulin, but not of the microtubule-affinity 
regulating kinase (MARK1) and microtubule-associated protein (MAP2), as described 
elsewhere (Miller, 2006, Moran, 2007). Recently, the underexpression of a set of genes that 
are expressed in response to the PPARGC1A gene has also been shown in patients with PD 
in a genome-wide expression study (Zheng, 2010). Activation of PPARGC1A results in 
increased expression of nuclear-encoded subunits of the mitochondrial respiratory chain 
(Zechner, 2010). Taken together, the results of Simunovic and co-workers are consistent with 
other observations that point to a functional disconnect of the striatonigral trophic signaling 
pathways (Miller, 2006). 
Currently, much data has been obtained regarding altered gene expression in brain tissues 
of patients with PD, especially in the substantia nigra. However, as can be seen in the 
studies described above, previous observations are reproduced rarely. Each study reports 
on different spectra of transcripts. The study of Moran et al. (Moran, 2006) is an exception, 
as it partly reproduced the results of Zhang et al. (Zhang, 2005), which can be explained by 
the fact that these authors used the same methods. Bossers et al. also replicated some of the 
results of Grünblatt et al. and Zhang et al. (ALDH1A1, SNCA, UCHL1, VMAT2, GBE1 and 
NR4A2) (Bossers, 2009). However, Moran et al. admit that they could not confirm the data of 
Grünblatt and Hauser, although they found similar changes in the expression of some genes 
,including ALDH1A1 and NR4A2. Such difference probably can be explained by the diverse 
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approaches in experimental design (different populations, different methods, and diverse 
comparison groups), despite the fact that all studies were performed using post-mortem 
samples of substantia nigra obtained from patients with PD.  
Given the apparent lack of concordance among published data sets, one might wonder 
about the relevance of these transcriptional approaches regarding PD pathogenesis. 
Certainly, the use of post-mortem brain tissues appears to represent the best opportunity for 
finding PD-specific changes in gene expression. Furthermore, such “benchmarks” facilitate 
the evaluation of clinical samples and model systems for their utility in PD research. 
However, the approaches used to generate and analyse microarray data are not 
standardized; therefore, they could account for much of the apparent discrepancy observed 
among reported gene lists (Sutherland, 2009). 
Nevertheless, despite the differences in individual gene expression data, many researchers 
report alterations in the expression profiles of whole groups of genes involved in specific 
cellular processes. Thus, a tendency toward downregulation of genes related to 
mitochondrial function and the ubiquitin-proteasomal system is observed, as well as the 
alteration of the expression of genes involved in oxidative stress, DA metabolism, transport 
proteins, microtubule-associated proteins of movement, and cytoskeletal proteins, thereby 
approving supposed picture of PD pathogenesis (Table 1). However, it is important to 
understand that alterations of expression likely represent late stages of PD (post mortem 
tissues) and cannot fully represent the entire pathogenesis of PD.  
Case-control expression analysis in a degenerative disease like PD raises difficult issues 
when attempting to uncover pathways contributing to disease initiation. It would be 
advantageous to target tissues that express the proteins that are fundamental to the disease 
process and that are different in individuals who are at risk for the disease. At the same 
time, we need to account for any influences of the pathological process on these profiles. 
Microarray data of predilection brain sites, such as the SN, illustrate the cytoarchitectural 
differences between cases and controls; however, to understand some of the early 
pathogenic processes, ideally we would want to assay a brain region that is very similar to 
the SN but that is only affected belatedly. 
The ability of the pathway approach that was used in the analyses of Sutherland and co-
workers (Sutherland, 2009) to provide adequate specificity for PD over other 
neurodegenerative conditions is an additional consideration. This issue remains unclarified 
and requires further investigation. It is important to recognize that there may be genetic 
expression patterns that are common among neurodegenerative diseases in general. These 
may reflect common pathological changes (such as cell death, markers of oxidative stress or 
neuroinflammation, and etc) or shared risk factors that influence neurodegeneration. 
Inherent difficulties remain regarding the generation of reproducible gene expression data 
from post mortem brain, even if an optimal region of the brain could be assayed. 
Furthermore, this information can only be used retrospectively, for the potential benefit of 
future PD patients. Therefore, there is considerable interest in developing strategies to 
obtain human RNA from sources that are more accessible, such as the blood or neuronal-
like cell lines. However, there is a real concern that peripheral tissues, such as whole blood, 
may express few proteins that are fundamental for the disease process and, therefore, may 
have limited ability to demonstrate case-control differences that are relevant to disorders of 
the nervous system (Matigian, 2008). The lack of available gene expression data from 
multiple tissues of patients with PD at various stages of the disease precludes such an 
analysis, but highlights the need for ongoing research efforts in this area. At present, the 
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search for expression markers of early stages of PD in tissues that are more available (e.g. 
blood and cerebrospinal fluid) is urgent. 
2.2 Analysis of gene expression in the peripheral blood of patients with PD 
Unfortunately, little is known currently about the expression of single genes and the 
expression profiles of groups of genes in the blood of patients with PD. Only a few studies 
report changes in the number of transcripts or protein concentration in blood cells or in 
plasma.  
To date, there is only one report of a genome-wide expression study in the blood of patients 
with PD. It was shown that only 22 among 20000 genes are significantly downregulateded 
in PD (Scherzer, 2007). According to other data, a decreased number of transcripts has been 
shown for two of these genes, HIP2 and ST13, in the substantia nigra of patients with PD 
(Table 1). However, Scherzer et al. noticed that one of the 22 genes that was most 
underexpressed in PD was the heat-shock protein-70-interacting protein ST13, which 
belongs to the ubiquitin–proteasome pathway. ST13 is a cofactor of the heat-shock protein 
70 (HSP70) and stabilizes its chaperone activity (Shi, 2007). HSP70 modulates the folding of 
SNCA and suppresses its toxicity in cells, yeast, and flies (Auluck, 2002, Flower, 2005, and 
Klucken, 2004, as cited in Scherzer, 2007). ST13 stabilizes the ADP state of HSP70, which has 
a high affinity for substrate proteins. Via its own chaperone activity, ST13 may contribute to 
the interaction of HSP70 with various target proteins (Hohfeld, 1995) that may play a role in 
the pathogenesis of PD. However, it is necessary to mention that we have not found any 
alterations in the expression of the ST13 gene in patients with PD in Russia (Shadrina, 2010).  
There are only a few studies on expression changes of single genes as well. Increased 
expression of SNCA was shown in the peripheral blood of Korean patients with a sporadic 
form of PD (Kim, 2004). Another study showed a direct correlation between the levels of 
expression of cyto/chemokines (MCP-1, RANTES, MIP-1-ǂ, IL-8, IFN-Ǆ, IL-1ǃ, TNF-ǂ, and 
NF-κB(p65)) in peripheral white blood cells in patients with PD and stages of PD (Reale, 
2009). These results reflect the deregulation of cytokines in the blood of patients with PD 
and possibly indicate the activation of inflammation. Recent data reported by Grünblatt et 
al., based on their previous study (Grünblatt, 2004), show that the expression levels of 
HIST1H3E, PSMA2, LAMB2, and ALDH1A1 may be biomarkers for PD diagnosis, with an 
achieved sensitivity and specificity of more than 80% (Grünblatt, 2010). However, the 
sensitivity of the clinical diagnosis of PD in symptomatic patients remains higher, as it is 
estimated as 91% (Hughes, 2002).  
Furthermore, some studies also described alterations of protein concentrations in the blood 
of patients with PD. Armentero et al. showed increased levels of glycogen synthase kinase 3 
(GSK-3) in peripheral lymphocytes in patients with PD (Armentero, 2010). GSK-3 has been 
implicated in the regulation of axonal transport (Morfini, 2002 and Pigino, 2003, as cited in 
Armentero, 2010) and modulates the ubiquitylation of synphilin-1, as well as its 
degradation, which is promoted by SIAH (Avraham, 2005, as cited in Armentero, 2010). 
Caronti et al. demonstrated a reduction of dopamine transporter immunoreactivity in 
peripheral blood lymphocytes in the early clinical stages of PD (Caronti, 2001). Despite these 
promising results, we have shown that the expression of GSK3B gene was not altered in the 
peripheral blood of Russian patients with PD (Filatova, 2011).  
Nevertheless, the study of gene expression in the blood opens broad prospects for the 
identification of biomarkers for diagnosis of PD. Expression-profile analysis in PD will 
possibly allow the elucidation of the pathogenesis of the early stages of PD, which, in turn, 
opens wide prospects for a more adequate treatment or preventive correction of this disease. 
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2.3 Analysis of gene expression in different models of PD 
Since the discovery of PD as a single nosological form, researchers have been trying to 
identify the mechanisms underlying disease development and approaches to test drugs 
before clinical usage. However, human brain tissues are not sufficient for these purposes 
because of their inaccessibility during the lives of the patients. Under these circumstances, 
researches have had to develop various models of PD involving cell lines (including 
induced pluripotent stem cells) and animals (mice, rats, monkeys, and flies). Currently there 
is a great variety of such models, which can be divided into two large groups: genetic 
(endogenous) and nongenetic (exogenous). Genetic models are based on altered expression 
of genes involved in the pathogenesis of PD or on altered functioning of proteins encoded 
by these genes. Nongenetic models are based on the introduction of different inductors (e.g. 
neurotoxins and drugs) into model organisms or on surgery approaches that lead to 
parkinsonian syndrome.  
Despite this variety of models of PD and their large impact on the elucidation of 
pathogenesis of this disease, the picture of the etiopathogenesis of the disorder remains 
approximate. Nevertheless, some reports describe changes in the whole transcriptome of 
model organisms.  
A monkey model with MPTP-induced parkinsonism was used to show that the same 
pathways are altered in the substantia nigra and in the striatum, as described previously in 
paragraph 2.1 and in Table 1 (Ohnuki, 2010); among them are mitochondrial dysfunction, 
oxidative stress, signal transduction, synaptic transmission, neurotransmitters, and 
neurotransmitter metabolism. Genes coding for the DA phenotype, such as DAT, AADC, 
TH, VMAT2, and ADLH1A1, were significantly downregulated in the SN of this MPTP, 
which is in line with the loss of DA neuronal function that occurs in PD and MPTP model 
systems. Genes involved in synaptic function and cytoskeletal stability represented a major 
class of genes that exhibited decreased expression. It was observed that some genes were 
consistently downregulated across the studies of PD patients. These genes were D4S234E, 
NSF, CADPS, SYNJ1, AMPH, MAP1B, MAPT, dynein complex component, kinesin family 
members, tubulins and catenins. Interestingly, the downregulation of D4S234E, which is a 
neuronal endosomal gene, showed the highest concordance across PD studies. This gene is 
involved in the regulation of AMPA-receptor trafficking in spines and may participate in the 
control of synaptic strength (Alberi, 2005, as cited in Ohnuki, 2010). The downregulation of 
the AMPA receptor GRIA3 was also consistently observed in PD studies. These observations 
may provide further insight for the evaluation of the neuroprotective effects of AMPA-
positive allosteric modulators for the treatment of PD (O'Neill, 2005, as cited in Ohnuki, 
2010). Downregulation of these synaptic transcripts in both MPTP models and PD patients 
suggests a significant failure in the production of the proteins necessary for vesicle 
trafficking and neurotransmitter release and transmission. The downregulation of several 
microtubule-associated proteins was also consistent in cross-comparison study (Ohnuki, 
2010). The downregulation of ACTR1A, which is a component of the dynein complex, and 
several kinesin family member genes (KIF3A, KLC1, KIF2A, and KIFAP3) was observed in 
both the SN and STR (striatum). As pointed out by Miller et al. (Miller, 2006), the dynein 
complex and the members of the kinesin family are particularly important for bidirectional 
axonal transport and for the understanding of the association between the SN and the STR. 
Together with the downregulation of cadherins (Miller, 2006) and the overrepresentation of 
the cell adhesion pathway in the STR, the deregulation of the cell adhesion process seems 
apparent (Ohnuki, 2010). 
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Multiple mechanisms have also been shown as involved in neuronal cell death in PD and 
model systems. Apoptotic cell death is one of the key mechanisms. Pathway enrichment of 
this category suggests its contribution to the cellular functions in PD and model systems. 
The observed upregulation of proapoptotic genes (BCL10 and TPD52L) and the 
downregulation of the antiapoptotic gene XIAP support the current concept of apoptosis in 
PD. Interestingly, XIAP is an ubiquitin–protein ligase of the UPS and has been shown to 
promote proteasomal degradation of caspase-3 and enhances its antiapoptotic effect 
(Ohnuki, 2010).  
The UPS is one of the most well studied contributors to neuronal cell death in PD and model 
systems. The UPS is involved in the protein disposal process in cells and exerts protective 
effects from toxic proteins (Duke, 2006). The consistent downregulation of UCHL1 across 
studies implies the impairment of the ability to degrade toxic proteins. Notably, the 
downregulation of ǃ-TrCP was found in the STR of the MPTP model (Ohnuki, 2010). ǃ-TrCP 
is a component of the SCF ubiquitin-ligase complex, which comprises SKP1, cullin, and the 
F-box protein. ǃ-TrCP functions as an F-box protein that recognizes specific targets for 
ubiquitination, thereby regulating the function of specific proteins, , including ǃ-catenin and 
NF-κB, via protein degradation. Interestingly, SKP1, which is another component of the SCF 
complex, is downregulated in the SN of PD patients, as assessed using microarray data 
(Mandel, 2005). Furthermore, a knockdown model of SKP1 exhibited increased 
susceptibility to cell death (Mandel, 2009). Thus, the reduction of SCF ubiquitin-ligase 
activity may play an important role in neuronal cell death both in the MPTP model and in 
patients with PD. MPTP-induced neuronal cell death is thought to affect surrounding cells 
to produce signals that feed back on the remaining DA neurons (Pattarini, 2008). Genes 
involved in neuroinflammation likely participate in this process. In agreement with earlier 
studies, treatment with MPTP led to the upregulation of the astrocyte marker GFAP. 
Although none of the typical microglial markers, such as CD40 and CD68, was detected in 
the study (Ohnuki, 2010), the upregulation of complement component genes (C1S and C4B), 
IL-11, and proinflammatory cytokines (CXCL13 and CXCL4) suggests microglial activation 
(Ohnuki, 2010). These observations support the notion that microglia-derived 
proinflammatory factors play a role in the process of dopaminergic MPTP-induced neuronal 
toxicity (Whitton, 2007).  
Neurotrophic support by neurotrophic and growth factors protects DA neurons (Evans & 
Barker, 2008). The observed downregulation of BDNF, FGF1, FGF13, and PACAP in the STR 
of the MPTP model is in agreement with previous evidence. Regarding BDNF, the PD 
patient study found a decrease in BDNF expression in nigrostriatal DA neurons (Nagatsu, 
2000). Certain transcription factors involved in survival and differentiation of DA neurons 
may participate in the neuroprotective function, as the loss of Nurr1 (NR4A2) (Ohnuki, 
2010). Therefore, the upregulation of factors such as Nurr1 and TCF7L2 may improve the 
protective effects against MPTP toxicity (Bassilana, 2005). Similar to this, the upregulation of 
TCF7L2 was observed in the SN of the MPTP model. In contrast, Ohnuki and co-workers 
found robust downregulation of TCF7L2 in the STR of the MPTP model. As activation of 
TCF7L2 by ǃ-catenin leads to the transcriptional initiation of the Wnt target genes (Clevers, 
2006), the downregulation of TCF7L2 may influence several genes associated with survival, 
differentiation, and cytoskeletal stability. However, there was low consistency across the 
data sets of patients with PD with the exception of the occipital cortex of patients with PD 
(Vogt, 2006). SKP1 was also downregulated in the same region and in the BA9 region of 
patients with PD (Vogt, 2006, Zhang, 2005). As the pathological process of Lewy bodies 
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begins in the brainstem and olfactory bulb and extends gradually to the substantia nigra 
and, ultimately, to the cerebral cortex (Braak, 2006), the deregulation of these genes may be 
associated with disease stage, in particular, with the late stage of PD. 
The mitochondrial dysfunction, oxidative stress, signal transduction, synaptic transmission, 
neurotransmitters, and neurotransmitter metabolism pathways were also altered in the 
mouse models described in two other reports (Chin, 2008, Smith, 2009). Similar results were 
obtained in the mice and cell models described by Chung et al. and Yacoubian et al. (Chung, 
2005, Yacoubian, 2008), although the two latter groups discovered changes mostly in the 
number of transcripts of regulatory genes.  
In addition, proof of the role of mitochondrial dysfunction in PD was obtained from a 
genetic (SNCA A30P) fly model of the disease (Xun, 2007). This finding additionally 
emphasizes the role of mitochondrial dysfunction in the pathogenesis of PD. 
Therefore, analysis of gene expression revealed that a number of significant pathways, 
including mitochondrial dysfunction, oxidative stress response, various transport pathways, 
signal transduction, synaptic transmission, neurotransmitters, neurotransmitter metabolism, 
and apoptosis, are involved in the development of PD. Nevertheless, much remains to be 
discovered to obtain the full picture of the pathogenesis of this disease. For example, the 
recently discovered microRNAs may offer new insight into the cellular mechanisms that 
occur during neurodegeneration.  
3. MicroRNA expression in Parkinson’s disease 
Currently, research on miRNAs in the context of neurodegeneration is accumulating rapidly; 
the goal of this review is to provide the most complete data on the expression of microRNAs in 
connection with the etiopathogenesis of Parkinson’s disease. Studies published recently shed 
some light on the role of microRNAs in the differentiation of dopaminergic neurons and raises 
the question of whether microRNAs are involved in the etiology of PD. There are also various 
reviews in this field (Barbato, 2009, Bushati & Cohen, 2008, De Smaelea, 2010, Fiore, 2008, 
Hébert & De Strooper, 2007, Lau & de Strooper, 2010, Nelson & Keller, 2007, Nelson, 2008, 
Roshan, 2009, Saugstad, 2010, Weinberg & Wood, 2009). 
Genome-encoded microRNAs (miRNAs) are known regulators of gene expression. The 
significance of miRNAs in various biological processes has been suggested by studies that 
showed an important role for these small RNAs in the regulation of cellular differentiation. 
However, the role of miRNAs in the regulation of the physiology of differentiated cells is 
not well established. Furthermore, the existence of neuron-specific miRNAs argues in favor 
of their important role in neuronal differentiation and/or specialized functions. The 
involvement of miRNAs in neuronal differentiation is strongly supported by dynamic 
changes in miRNA expression during brain development (Krichevsky, 2003, Miska, 2004, 
Smirnova, 2005). The significance of miRNAs in neuronal physiology is also suggested by 
data that show miRNA involvement in dendritic-spine formation and neurite outgrowth in 
vitro (Schratt, 2006, Vo, 2005). In summary, although there is mounting evidence of the 
importance of the roles of miRNAs in neuronal cell differentiation, their role in 
differentiated, postmitotic neurons has not been addressed fully (Schaefer, 2007).  
3.1 What is a microRNA? 
miRNAs are a class of small noncoding RNAs that induce translational repression or 
degradation of a target mRNA upon imperfect base pairing to its 3’ untranslated region 
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(3’UTR). The biogenesis and mechanism of action of miRNAs are covered in detail in a 
number of excellent reviews (Bartel, 2004, Bartel, 2009, Bushati & Cohen, 2007), therefore, it 
will be summarized briefly here. Structurally, mature miRNAs are single-stranded RNA 
molecules of about 21 nucleotides (nt) derived from a 70-100 nt hairpin precursor (pre-
miRNA). miRNA genes are mostly transcribed by RNA polymerase II, with the exception of 
some human genes that are transcribed by RNA polymerase III (Borchert, 2006). The 
primary transcript, which can be up to hundreds of nt long, is then processed by the RNAse 
III enzyme Drosha in the nucleus, to yield a pre-miRNA. The pre-miRNA is subsequently 
translocated to the cytoplasm via an exportin-5-dependent mechanism. Once in the cytosol, 
pre-miRNAs are further processed by a second RNAse III enzyme, Dicer. Cleavage 
generates an imperfect, siRNA-like duplex that is unwound and whose strand with the 
weakest base pairing at the 5’ end is preferentially loaded into the RNA-induced silencing 
complex (RISC). Binding of the miRNA to its target occurs within the RISC and target 
silencing requires the presence of proteins belonging to the Argonaute (AGO) family. 
Complementarity between the 5’ end of the miRNA, the seed region, and the 3’UTR of the 
target mRNA appears to be critical for the binding, where more variability is tolerated in the 
base pairing at the 3’ end of the miRNA (Bartel, 2004, Bushati & Cohen, 2007). However, the 
range of action of miRNAs remains under active debate, as others showed that miRNAs are 
only active onto 3’UTR (Gu, 2009). Moreover, the mechanisms of miRNA processing at the 
posttranscriptional level are only beginning to be elucidated (Lau & de Strooper, 2010). 
miRNAs regulate approximately 30% of genes in the human genome (Rajewsky, 2006). The 
mechanism by which miRNAs silence gene expression remains an active and controversial 
field of investigation (Cannell, 2008, Filipowicz, 2008, Lau & de Strooper, 2010, Vasudevan, 
2007). Single miRNAs are able to target up to a few hundreds of different mRNAs 
(cooperativity) (Brennecke, 2005, John, 2004, Krek, 2005, Lewis, 2005). It is hardly surprising 
that the number of roles assigned to miRNAs during all stages of central nervous system 
(CNS) development and function is rapidly expanding (Fiore, 2008). One of the main 
mechanisms appears to be the blocking of translational initiation, but other mechanisms are 
likely involved (Jackson & Standart, 2007, Pillai, 2007, Standart & Jackson, 2007). Processing 
bodies (Pbodies), which are cytoplasmic foci that were originally identified as sites of 
mRNA storage and degradation, are critical structure for miRNA-mediated deadenylation 
and degradation. In addition to Pbodies, neurons contain a variety of functionally related 
high-molecular-weight ribonucleoprotein particles (nRNP) that are involved in the storage, 
dendritic trafficking, and translational control of neuronal mRNAs (Barbee, 2006, 
Krichevsky & Kosik, 2001).  
Elucidation of the precise biological functions of these miRNAs has been the subject of many 
studies. miRNAs are involved in cell differentiation, development, apoptosis, stress 
resistance, tumor formation, and in neurodegenerative disorders (Bushati & Cohen, 2008, 
Plasterk, 2006, Santosh, 2009). Earlier studies provide some evidence of the involvement of 
miRNAs in Parkinson’s disease (Nelson, 2008), but do not offer a full, comprehensive view 
of the microRNA-dependent regulation of PD genes. 
It is possible that simple computational prediction of microRNA targets will shed some light 
on the behavior of target genes involved in Parkinson’s disease. In addition, the 
identification of mRNA targets currently relies on prediction software (Bartel, 2009). 
Prediction of miRNAs using computer-based methods exhibits many advantages and aids 
in recognizing the molecular hallmarks of the disease that can lead to the development of 
effective screening tools for miRNA targets. However, the prediction of microRNA targets 
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may be hindered by numerous problems, including tissue-specific expression and lack of 
validation. Moreover, interpretation of results is often not as evident and is further 
complicated by the small overlap set of predictions when comparing different algorithms. 
Such weakness of in silico studies can be partially compensated by predicting targets using 
multiple programs. The outputs can be effectively used for the development of a molecular 
marker for diagnosis and prognosis. Computer-based prediction of microRNA target 
selection undoubtedly reduces the noise, but is not sufficient to estimate the efficiency of 
each microRNA on the multiple targets. Therefore, computational prediction may not guide 
optimized selection of any single microRNA for efficient knock down and level of action; 
further validation of these findings using experimental approaches is required. Additional 
analysis and experimental validation of these results is mandatory to resolve the complexity 
of the selection of microRNA targets in the future (Santosh, 2009). 
3.2 MicroRNAs in Parkinson’s disease 
As stated earlier, some studies provide evidences of the involvement of miRNAs in 
Parkinson’s disease (Nelson, 2008), but they do not offer a full, comprehensive view of the 
microRNA-dependent regulation of PD genes. However, a causal link between a specific 
miRNA and a disease has been established in just a few cases, and most of the mechanistic 
data originate from invertebrate model systems.  
An important work regarding the role of miRNAs in PD performed in Asa Abeliovich’s 
laboratory indicates that a particular miRNA plays a significant role in the pathogenesis of 
this disease (Kim, 2007). Kim et al. profiled a panel of 224 miRNA precursors from the 
brains of Parkinson’s patients and found that several miRNAs were deregulated, including 
the downregulation of miR-133b, which is enriched in dopaminergic neurons of the 
midbrain and, if overexpressed, suppresses their maturation and function. The authors 
showed experimentally that miR-133b is relatively highly expressed at the tissue level in the 
midbrain under normal conditions, but not in PD. Furthermore, the general knockout of 
miRNAs in vivo, or of miR-133b by itself in cultures of dopaminergic neurons, cultures 
derived from ES cells, or midbrain cultures, dramatically decreases the levels of tyrosine 
hydroxylase and dopamine transporter in dopaminergic neurons. Mir-133 appears to act as 
a negative regulator of dopaminergic neuron maturation, as overexpression and inhibition 
of miR-133b resulted in the decrease and increase, respectively, of the number of DA 
neurons in these cultures. The data also support the hypothesis that miR-133b and the 
paired-like homeodomain transcription factor PITX3 regulate each other’s expression. In 
homology with miR-124, miR-133b seems to be a component of a negative feedback loop. In 
this case, miR-133b targets the transcription factor and marker for DA neurons, PITX3, 
which in turn is a positive regulator of miR-133b. Thus, loss of Pitx3 leads to the loss of miR-
133b in the PD model. Interestingly, aphakia mice are deficient in Pitx3, which is a 
homeobox transcription factor required for the survival of DA neurons and for motor 
activity (van den Munckhof, 2003, as cited in Fuchs, 2007). Polymorphisms in PITX3 have 
also been associated with PD in humans (Bergman, 2008, Fuchs, 2007). 
This study is important for a number of reasons. First, it indicates a discrete role for a 
particular miRNA in dopaminergic function. Second, no particular miRNA–mRNA pair had 
been strongly implicated previously in a prevalent neurodegenerative disease. In other 
words, these investigators provided plausible molecular neurobiological breakthroughs for 
both miRNA function and dysfunction. This study also demonstrates how miRNAs can be 
an important component of a “downward spiral” during neurodegeneration (Nelson, 2008). 
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Whether the loss of the miRNA contributes to the etiology of PD is an important, albeit 
unanswered, question. This has not been addressed directly in the mouse model because 
mutants lacking miR-133b are not available. 
The relationship between miR-133b and the maturation of DA neurons is especially 
intriguing, for two reasons. Firstly, mice with a conditional deletion of Dicer in DA neurons 
display progressive loss of DA neurons (Kim, 2007). Importantly, this phenotype is also 
observed in vitro in a dopaminergic stem cell differentiation paradigm, and can be partially 
rescued by transfection of the cultures with a small RNA population isolated from wild type 
cells. Secondly, and puzzlingly, miR-133b is undetectable in the midbrain of patients with 
Parkinson’s disease (Kim, 2007). This apparent contradiction awaits further validation; 
however, it strongly suggests additional functions of miR-133 in DA neurons. 
Interestingly, neurodegeneration is also observed in mice that lack Dicer specifically in the 
cerebellum. In these animals, Purkinje neurons progressively degenerate and the animals 
develop ataxia (Schaefer, 2007). Authors demonstrated an essential role for Dicer and 
miRNAs in the regulation of postmitotic neuronal survival. Although Dicer deficiency had 
no immediate impact on Purkinje cell function, the long-term absence of Dicer resulted in a 
neurodegenerative process. This pattern of Purkinje cell degeneration in the absence of 
miRNAs bears obvious similarities to processes associated with the slow, progressive 
neurodegenerative diseases, such as Alzheimer’s and Parkinson’s diseases. Deletion of Dicer 
impairs the ability of embryonic stem cells to differentiate into DA neurons, by blocking 
miRNA biogenesis. As Dicer deletion was partially rescued by transfection of a small RNA 
derived from embryonic mouse midbrain, it is likely that microRNAs are involved in the 
differentiation and survival of DA neurons (Kim, 2007). In addition, specific deletion of 
Dicer in vivo, in mouse midbrain dopaminergic neurons, leads to cell death in the substantia 
nigra. Behavioral studies of these animals revealed reduced locomotion in an open-field 
assay, which was reminiscent of the phenotype of human patients with PD. Thus, although 
miR-133b is involved in the differentiation and function of DA neurons, additional 
microRNAs should be responsible for the Dicer deletion phenotype in DA neurons 
(Sethupathy & Collins, 2008). 
Together, these observations raise the possibility that the loss of miRNAs is involved in the 
emergence and/or progression of PD. Although its expression is lost in PD samples, these 
findings indicate that miR-133b cannot be the miRNA species that is responsible for the 
embryonic stem cell Dicer phenotype or the progressive loss of mouse midbrain DA 
neurons in Dicer mutants. PD probably results from the loss of PITX3-dependent expression 
of genes other than miR-133b. The miRNA(s) carrying a protective potential against DA 
neuron neurodegeneration remain unidentified. This profound loss of DA neurons in the 
substantia nigra contrasts with results of a study in which Dicer was removed from the 
dopaminoceptive neurons of the striatum (Cuellar, 2008). A range of phenotypes was 
observed, including reduction of the size of the brain and of neurons, ataxia, wasting, and 
premature death; however, the dopaminoceptive neurons survived throughout the lives of 
the animals. Therefore, in general, Dicer does not seem to be required for the promotion of 
cell survival in all postmitotic neurons, as Dicer is also dispensable in mature olfactory 
neurons (Choi, 2008). Notably, dysfunction, but not necessarily extensive loss, of 
dopaminoceptive neurons has also been implicated in PD (Evans & Lees, 2004). 
Another miRNA has also been associated with the development of PD. A linkage analysis in 
PD reported in 2001 for identified a linkage peak on chromosome 8 that harbored the 
fibroblast growth factor 20 (FGF20) gene (Scott, 2001), which is preferentially expressed in 
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the substantia nigra and promotes the survival of dopaminergic neurons. A subsequent 
Comparative Genomic Analysis Study (CGAS) reported in 2004 identified rs1989754 within 
FGF20 as associated with PD (van der Walt, 2004). Therefore, Wang et al. (Wang, 2008) 
selected FGF20 for further association testing using a family-based design. The authors 
observed that the strongest association (P = 0.0001) occured with rs12720208 [C/T], a SNP 
that was demonstrated as mediating the allele-specific in vitro targeting of miR-433 to the 
3’UTR of FGF20. The authors also showed that miR-433 is highly expressed in the brain. 
Unlike prior studies, these researches went even further by providing human in vivo 
validation and testing a molecular mechanism by which differential miR-433 targeting 
potentially leads to PD. In cell culture experiments and in PD brains, increased translation of 
FGF20 was correlated with increased expression of ǂ-synuclein.  
Two independent GWASs for PD did not test rs12720208 (Fung, 2006, Maraganore, 2005). 
However, one of these studies tested a nearby SNP (rs1989754) and found no signal for 
association (P = 0.40) (Fung, 2006). The other study also tested another SNP within FGF20 
(rs17515020) and observed a modest signal for association with PD (P = 0.03) (Maraganore, 
2005). However, this result was not significant after correction for multiple testing 
(Maraganore, 2005). According to the phased HapMap CEU genotype data, rs12720208 is 
not in strong LD with either rs1989754 (r2 = 0.1) or rs17515020 (r2 = 0.029); therefore, this 
SNP may still be associated with PD independently. Given that this study was not 
confounded by population stratification because of the use of a family-based association 
study design, and given that there is compelling functional evidence for both allele-specific 
targeting and an underlying molecular mechanism for the role of miR-433–FGF20 in PD 
pathogenesis, rs12720208 is the most attractive human poly-miRTS for use in future 
replication studies (Sethupathy & Collins, 2008). However, there was no association between 
the FGF20 SNP rs12720208 and Parkinson’s disease in Spanish patients (de Mena, 2010). 
Overexpression of SNCA appears to be a common feature in PD and other ǂ-
synucleinopathies. In addition, it was demonstrated recently that miR-7 interacts in vitro 
with the 3’UTR of SNCA, represses the expression ǂ-synuclein and inhibits ǂ-synuclein-
mediated cell death (Junn, 2009). Of note, miR-7 inhibits the cellular susceptibility of 
neuroblastoma cells to oxidative stress induced by a mutant form of SNCA, providing 
evidence that miRNAs protect neuronal cells against cellular stress. The presence of miR-7 
in the substantia nigra was also validated, thus supporting a physiological role for this 
molecule in DA neurons. However, miR-7 was initially reported as highly expressed in the 
mouse pituitary gland (Bak, 2008, as cited in Lau & de Strooper, 2010) and its expression 
was ~15-fold lower in the substantia nigra compared with the pituitary gland, leaving open 
the possibility that other miRNAs regulate dopaminergic neurons in amore dynamic and 
efficient manner (Lau & de Strooper, 2010).  
One of the latest studies on this subject revealed a previously unknown mechanism of 
regulation of SNCA levels in the nervous system (Doxakis, 2010). Specifically, two brain-
enriched miRNAs, miR-7 and miR-153, were shown to bind directly to the 3’UTR of the 
SNCA mRNA and reduce its levels significantly. RNA and protein expression analysis 
showed developmental and tissue coexpression among miR-7, miR-153, and SNCA. The 
results of the study indicate that miR-7 and miR-153 have synergistic effect, require the 
3’UTR of SNCA mRNA to regulate SNCA protein expression, do not interact with the 
coding region of SNCA to regulate the expression of SNCA protein, and act at the 
pretranslational level. Taking into consideration the two types of miRNA function, these 
findings strongly suggest that miR-7 and miR-153 play a role in the modulation/buffering of 
SNCA protein levels in the nervous system. 
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As neither of the miRNAs is fully complementary to the SNCA mRNA — to allow 
endonucleolytic cleavage by Argonaute proteins — the degradation effect is likely to stem 
from the accelerated level of deadenylation and decapping of the SNCA mRNA, induced by 
the binding of miR-7 and miR-153 to its 3’UTR (Behm-Ansmant, 2006 and Eulalio, 2009, as 
cited in Doxakis, 2010). miR-7, miR-153, and the SNCA mRNA and protein show highest 
expression in neural tissues, such as the midbrain, hippocampus, and cortex (the levels of 
miR-7, miR-153, and SNCA mRNA are significantly higher in neurons compared with 
astrocytes), and lowest expression in nonneural tissues, such as the lung and heart. 
Interestingly, all three RNA species show highest expression in the midbrain, indicating that 
deregulation of their expression levels may be important in the pathogenesis of PD. The 
SNCA protein is also detected in the lung, as a result of the high amount of peripheral blood 
present in this tissue. Moreover, the expression profiles of the SNCA mRNA and protein are 
similar, indicating that, during development, a constant level of the miRNA-regulated 
SNCA mRNA is translated into protein. These results suggest that miR-7 and miR-153 are 
coexpressed with SNCA in neurons to regulate its levels via a transcriptional feed-forward 
loop that fine-tunes, rather than blocks, the expression and translation of the SNCA mRNA 
(Doxakis, 2010). 
4. Conclusions 
Most neurochemical and gene expression studies on the mechanism of DA neuron death in 
PD and its animal models, have been conducted at a time when the majority of dopamine 
neurons are dead. However, the detailed profile of the crucial initial neurochemical and 
gene expression changes in injured (but not dead) neurons is more important, as the early 
genetic and biochemical alterations differ from those that occur at the time of neuronal 
death. 
It is also important to emphasize that mRNA data reveal information on the transcriptional 
activation of genes, but do not provide much information on the actual protein levels and 
function. In addition, array data cannot predict whether deregulated gene expression is a 
primary or a secondary effect of cell function. For example, a gene could be down- or 
upregulated by factors such as miRNAs or transcriptional activators (or inhibitors), 
independent of its protein function and/or as a consequence of positive and negative 
feedback loops. Moreover, protein function relies on the interaction of down- and upstream 
factors within a pathway, i.e. downstream factors are more dependent on upstream 
signaling compared with upstream factors, which may influence a cascade of downstream 
events that can include multiple pathways. Thus, the consequences of deregulated gene 
expression are exerted on multiple levels within a complex and dynamic interplay of factors 
and mechanisms. Laser-microscopy-based microarray studies can only provide a 
“snapshot” of these events. Nevertheless, several studies showed that many genes 
associated with the pathogenesis of Parkinson’s disease are deregulated in single captured 
postmortem DA neurons. This could provide a “molecular fingerprint identity” of a late-
stage DA neuron affected by sporadic Parkinson’s disease. The striking downregulation of 
PARK genes is a key aspect. As their mutation-induced malfunction in the familial forms of 
Parkinson’s disease rapidly accelerates DA neuron degeneration, the results from the 
studies reviewed may support the view that these genes are also involved in the 
pathogenesis of sporadic Parkinson’s disease. Data also point to an imbalance in neuronal 
homeostasis and stress characterized by factors related to high metabolic rate, 
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neurotransmission and ion-channel activity. This stress may be part of the normal 
homeostasis and aging of DA neurons, but could be exacerbated in the presence of an 
unfavorable imbalance. In addition, the array data suggest a disintegration of key cellular 
functions, such as mitochondria-associated energy metabolism, protein degradation, 
synaptic function, and cytoskeletal integrity, revealing a cellular state that is characterized 
by programmed cell death. However, despite this cellular demise, some genes linked to 
survival mechanisms were upregulated, indicating the activation of compensatory 
mechanisms. Finally, the lack or the relatively modest deregulation of genes important for 
the DA neuronal phenotype suggests that the DA neurotransmitter identity (including DA 
production) seems to be sustained even when the neurons are severely damaged. It appears 
that the gene expression profile of the DA neurons of late-stage Parkinson’s disease is 
consistent with the view that Parkinson’s disease is a complex disorder and that multiple 
factors and cellular pathways are involved in its pathogenesis. 
To date, whether miRNAs are also actively involved in the etiology or progression of 
neurodegenerative disorders remains uncertain. These small regulators clearly seem to be 
required for the survival of specific types of mature neurons in some model organisms; 
however, whether the loss of individual miRNAs can account for the drastic disease 
phenotypes remains to be determined. As many different cellular processes have been 
implicated in neurodegenerative disorders, the miRNAs involved in these pathways will 
obviously be found as misregulated in disease tissues. However, the degree to which their 
misregulation is causative in the diseases remains a pressing, but unanswered, question. 
Identification of causal links opens prospects for therapeutic intervention, perhaps by 
replacing missing miRNAs or blocking the activity of miRNAs that are overexpressed. 
Similarly, some miRNAs seem to have a neuroprotective role; therefore, they could 
potentially be used to prevent, or at least decelerate, the progressive loss of neurons in the 
diseased brain. These are tantalizing prospects that remain far from our grasp (Bushati & 
Cohen, 2008). Studies of miRNA in neurodegenerative diseases are emerging. Currently, 
both changes in the expression profiles of several miRNA and polymorphisms affecting the 
interactions between miRNAs and their targets are being addressed in various studies on 
neurodegenerative disease. It is difficult to determine if the changes in miRNA expression 
detected in the brains or cerebrospinal fluid (CSF) of patients are primary or secondary 
events, or both. Nevertheless early or late in the evolution of the disease, they may 
contribute to the pathogenesis of the observed lesions and neuronal loss. Unique patterns of 
miRNA expression in the CSF of particular neurodegenerative diseases may be useful as 
molecular biomarkers for disease diagnosis and, eventually, for the prediction of therapeutic 
responses. The identification of miRNAs that cause a specific pathology could open new 
therapeutic perspectives to block endogenous miRNAs or deliver exogenous miRNAs. To 
date either antisense oligonucleotides that are chemically modified (Meister, 2004) or 
expressed sequences corresponding to multiple miRNA seed targets (miRNA sponge) 
(Ebert, 2007) have been used as microRNA inhibitors. Delivery of these molecules to the 
central nervous system, while avoiding toxicities, may be the challenge of future research in 
this area. Furthermore, as specific nuclear or cytoplasmic protein accumulation causes the 
neuropathological manifestation in several neurodegenerative disorders, the identification 
of microRNAs that regulate the translation of these targets may represent the first step 
toward therapeutic applications. The second step might be the evaluation of the quantitative 
effects of specific amounts of “therapeutic” microRNAs on the proteome (Barbato, 2009). 
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